Key Points
(JB Pharma), majority owned by private equity firm KKR, is scouting for more acquisitions to broad base its offerings as well as to grow its ranking in the Indian pharmaceutical sector...
In October 2020, KKR picked up 54% stake in JB Pharma from the erstwhile promoters of the company for about $550 million and since then the company, under the leadership of Mr. ,Chopra and the management team, has embarked on high growth path...
It wants to further strengthen its offerings in the chronic disease segment, Mr. Chopra said.. JB Pharma is now the most valuable company in the listed Indian Pharma sector withEV/EBITDA at 20 times vs 15-16 times of leading pharma companies..
We are nowthe fastest growing pharmaceutical company in India Pharma Market for the 2nd consecutive calendar year, he said.. With brands like Rantac, Metrogyl and Cilacar touching millions of patient lives across the country, he said seven brands of the company nowfeature in the top 300 Indian pharmaceutical brands...
He said the company continuously develops innovative products for its big brands like Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl DG Gel, Nicardia XL, Sporlac EVA, Sporlac GG that caters to a wide patient profile in respective therapeutic categories...
